Quick Answer
Tevogen Bio Holdings Inc. reported Net Income of -$26.28 million for fiscal year 2025.
Tevogen Bio Holdings Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$26.28M -91.4% |
-$13.73M +77.3% |
-$60.48M -1471.9% |
$4.41M | — |
| Diluted EPS | -$8.08 -130.9% |
-$3.50 -43.4% |
-$2.44 | — | — |
| Total Assets | $4.38M +26.6% |
$3.46M -37.1% |
$5.51M -98.5% |
$357.14M +1.2% |
$352.85M |
| Cash and Equivalents | — | — | — | $129.2K -62.5% |
$344.6K |
| Stockholders Equity | -$8.23M -23.4% |
-$6.67M +92.9% |
-$94.43M -178.1% |
-$33.95M | $0.00 |
| R&D Expense | $11.11M -64.2% |
$31.03M +604.7% |
$4.40M | — | — |
| Operating Income | -$26.14M +51.2% |
-$53.56M -505.7% |
-$8.84M | — | — |
| Shares Outstanding | 4.02M +22.1% |
3.29M -97.3% |
120.00M +4935.6% |
2.38M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$5.73M | +2.7% | -4.0% |
| Diluted EPS | September 30, 2025 | -$0.03 | +0.0% | +0.0% |
| Total Assets | September 30, 2025 | $4.49M | +4.8% | +5.3% |
| Cash and Equivalents | September 30, 2022 | $143.0K | — | -22.9% |
| Stockholders Equity | September 30, 2025 | -$7.82M | -26.4% | +17.5% |
| R&D Expense | September 30, 2025 | $3.11M | -4.6% | +15.2% |
| Operating Income | September 30, 2025 | -$5.73M | +5.9% | -5.2% |
| Shares Outstanding | September 30, 2025 | 197.39M | +15.6% | +1.9% |
- Tevogen Bio Holdings Inc. reported Net Income of -$26.28 million for fiscal year 2025.
- Tevogen Bio Holdings Inc. showed a decrease of -91.4% in Net Income compared to the prior fiscal year.
- Tevogen Bio Holdings Inc. reported Diluted EPS of $8.08 per share (loss) for fiscal year 2025.
- Tevogen Bio Holdings Inc. showed a decrease of -130.9% in Diluted EPS compared to the prior fiscal year.
- Tevogen Bio Holdings Inc. reported Total Assets of $4.38 million for fiscal year 2025.
- Tevogen Bio Holdings Inc. showed an increase of +26.6% in Total Assets compared to the prior fiscal year.
- Tevogen Bio Holdings Inc. reported Cash and Equivalents of $129.2 thousand for fiscal year 2022.
- Tevogen Bio Holdings Inc. showed a decrease of -62.5% in Cash and Equivalents compared to the prior fiscal year.
- Tevogen Bio Holdings Inc. reported Stockholders Equity of -$8.23 million for fiscal year 2025.
- Tevogen Bio Holdings Inc. showed a decrease of -23.4% in Stockholders Equity compared to the prior fiscal year.
- Tevogen Bio Holdings Inc. reported R&D Expense of $11.11 million for fiscal year 2025.
- Tevogen Bio Holdings Inc. showed a decrease of -64.2% in R&D Expense compared to the prior fiscal year.
- Tevogen Bio Holdings Inc. reported Operating Income of -$26.14 million for fiscal year 2025.
- Tevogen Bio Holdings Inc. showed an increase of +51.2% in Operating Income compared to the prior fiscal year.
- Tevogen Bio Holdings Inc. reported Shares Outstanding of 4.02 million shares for fiscal year 2025.
- Tevogen Bio Holdings Inc. showed an increase of +12.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: